Applied Aerospace & Defense: the growth is real, the cash is not yet

Applied Aerospace & Defense builds composite and metal structures, precision strike components and space hardware, and it has the order book to prove demand is strong. Second quarter revenue rose 47.4%, or 19.8% without the 2026 acquisitions. But in the first half the company burned $103.7 million of free cash flow, most of its growth was bought, and a sponsor still owns about 80% of the shares. At $12.03 the market already assumes almost no EBITDA growth. The open question is whether the cash shows up.

At $12.03 on September 30, 2026, the shares trade 18.9% below my triangulated Base value of $14.84, and 39.9% below the $20 IPO price. The Bear value of $10.36 is 13.9% below the price. The required margin of safety of 50% puts the maximum buy price at $7.42. For existing holders this is a hold. For new money it is a watchlist name.

Route: SF-13 Industrials and manufacturing, aerospace and defense advanced manufacturer. Economic classification: Quality Growth (6/12, partial scorecard). Primary method: forward EV to 2027 adjusted EBITDA. Secondary method: price to 2028 free cash flow, discounted to today. Values are present fair-value estimates, not 12-month price targets.

What Applied is

Applied provides design, engineering and vertically integrated manufacturing for space and defense customers across three markets. In the second quarter, Space and Launch Systems brought in $38.8 million of revenue (up 58.5%), Defense Aviation and Airborne Systems $78.9 million (up only 4.8%) and C5ISR and Precision Strike Systems $49.6 million (up 261.6%, mostly from the CBI acquisition). In other words, the largest legacy segment is growing slowly, and the headline growth comes from space and from acquired precision strike capacity.

The company is a controlled company: AA&D Holdings, its sponsor parent, owned about 80% of the shares at June 30, 2026. Management has bought growth aggressively. CBI, acquired on March 2, 2026 for $374.8 million, added $43.2 million of revenue between its closing date and June 30. Goodwill and intangibles now equal about 62% of total assets.

The latest quarter

Management reaffirmed 2026 guidance of $670 to $690 million of revenue and $150 to $155 million of adjusted EBITDA, and said some second quarter revenue was pulled forward from the second half. The guidance midpoints imply second half revenue of about $378 million and adjusted EBITDA of about $89.5 million, a 23.7% margin. The first half margin was 20.9%. Reaching the guide needs a clear step up in profitability, not just more revenue.

Why adjusted EBITDA is not yet cash

First half adjusted EBITDA was $63.0 million, but operating cash flow was -$82.1 million. About -$35.4 million of that came from the earnings line itself after $40.8 million of cash interest and acquisition and IPO costs. The other -$47.8 million came from working capital: a $44.2 million build in contract assets (revenue recognized before it is billed) and a $23.3 million drop in accrued liabilities, partly offset by lower receivables and inventory. Adding back $23.5 million of transaction and integration costs still leaves first half free cash flow near -$80 million.

Part of this is one-off, because the IPO repaid most of the debt that drove the interest bill. But the contract asset build is a real feature of defense manufacturing, and it is the number to watch. Third-party consensus for 2026 free cash flow is about -$57 million, which would need roughly +$47 million in the second half. Hard metric: free cash flow after required reinvestment. Headline metric: adjusted EBITDA. In the first half the conversion was negative, so the valuation below leans on estimates of conversion that have not yet been demonstrated.

Cash, debt and shares

At June 30, 2026, cash was $18.1 million, term debt principal $405.8 million and finance lease liabilities $31.0 million, for net debt of $418.7 million including leases ($387.7 million without them). That is about 2.75x the 2026 adjusted EBITDA guidance midpoint, with $125 million of revolver capacity undrawn. The IPO sold 34.15 million shares at $20 and raised $635.6 million, of which about $626.2 million went to repay borrowings and accrued interest. Yet total debt fell only $237.6 million since year end, because the CBI deal added $361.1 million of new debt in March.

Shares rose from 129.7 million at year end to 172.4 million on August 5, 2026, up 32.9%, from the IPO and 8.6 million shares issued to the parent for CBI. First half stock compensation of $110.8 million was almost entirely a one-time vesting of incentive units at the IPO. The run rate of stock compensation under the new public company plan is not disclosed, so I use 172.39 million shares and test dilution below.

Primary valuation: forward EV to adjusted EBITDA

The primary Base value is $16.01: 17x on $187 million gives an enterprise value of $3.18 billion, less $418.7 million of net debt, or $2.76 billion of equity over 172.39 million shares. The $187 million is my 2027 estimate. On about $787 million of 2027 revenue (third-party consensus) it implies a 23.75% margin, above the 22.4% guided for 2026 but in line with the 23.5% pro forma margin of 2025. The 17x multiple is an assumption in the lower half of the framework's 15x to 22x tier for defense companies, between the 14x Bear and the 19.5x Bull. Because the company has no free cash flow per share history and a return on capital of about 6% in 2026 and 8% in 2027 on my estimates, I give it no premium for return on capital and only a limited one for growth.

Secondary valuation: price to 2028 free cash flow

Estimated 2028 free cash flow is about $98.3 million (third-party consensus datasets that I could not reproduce from free sources, so treat it as an estimate). At 25x, equity is worth $2.46 billion, or $14.26 per share. That value belongs to the end of 2027, so I discount it 1.25 years at 10%, the top of the framework's 8% to 10% range, to get $12.65 today ($12.95 at 8%).

Historical cross-check and growth diagnostic

There is no meaningful trading history: the shares listed in June 2026, peaked at $24.24 on July 1 and fell to a low of $11.39 on September 11. The $20 IPO price is a reference point, not a value, so it gets no weight.

The growth valuation cross-check (SM-19) is not meaningful. Net loss per share was -$1.04 in the second quarter and adjusted 2026 EPS consensus is about -$0.88, so a forward PEG would divide by growth from a negative base, and the free cash flow growth ratio cannot be computed. Data providers show a forward P/E of about 30x to 32x on 2027 adjusted EPS of about $0.40, but GAAP and adjusted results differ by more than $100 million of stock compensation, so it is not used. Growth durability: acquisition affected and structural. Cyclical distortion: low. Flags: PEG not meaningful, accounting basis mismatch. This diagnostic does not set fair value.

Valuation triangulation

The two methods diverge by 23.4%, above the framework's 20% warning line. The cause is the cash conversion gap: EBITDA says $16, free cash flow says under $13. Confidence is not raised, valuation robustness loses a point and the margin of safety rises. The secondary method exists only for the Base case, so the Bear and Bull values come from the primary method alone.

What is the market already pricing in?

At $12.03, market value is about $2.07 billion and enterprise value about $2.49 billion including finance leases. That is 16.3x the 2026 adjusted EBITDA guidance midpoint and 13.3x my 2027 estimate. If the market pays 17x, the price implies 2027 EBITDA of only about $147 million, below the 2026 guidance of $152.5 million. Put differently, the market is either assuming no EBITDA growth, or demanding a 13x multiple for $187 million. To get upside, an investor must believe that organic growth stays in the teens, that margins climb to 23% or more, that free cash flow turns positive in the second half, and that the acquisitions earn their cost of capital.

Bear, base and bull scenarios

Bear: growth outside the acquisitions slows to about 10%, integration costs hold the margin near the first half level of 21%, and the market stops paying for growth that does not convert to cash. Base: consensus revenue, the margin returns to its 2025 pro forma level and free cash flow improves. Bull: high teens organic growth, clean backlog conversion, margin expansion and a premium defense multiple. The Bear cuts both EBITDA and the multiple, and they share one cause, unproven cash conversion, so I limited the multiple cut to 14x, still inside the framework's 12x to 18x quality tier rather than the 8x to 12x industrial tier.

Sensitivity: primary value per share

How the buy price is set

Confidence C starts at a 40% margin of safety. Five points are added because adjusted EBITDA has not converted to cash and the adjustments are large, and five for the 23.4% divergence between the two methods, for 50%. A 50% discount to the $14.84 Base gives a maximum buy price of $7.42. A deeper 60% discount gives $5.93, so the buy zone is $5.93 to $7.42.

Dividend

Applied pays no dividend and is not an income thesis. Capital allocation should be judged on deleveraging, acquisition returns and free cash flow per share.

Reasons to own AADX

• Visible demand. $1.13 billion of backlog and $947.6 million of remaining performance obligations, with about $464 million due to convert in 2027.
• Real organic growth. Revenue grew 19.8% in the second quarter excluding 2026 acquisitions, and space revenue rose 58.5%.
• An IP rich, vertically integrated position. Mission critical subsystems made with specialized materials and processes are hard for a customer to replace quickly.
• Deleveraging. The IPO used about $626 million to repay borrowings and interest and cut net debt to roughly 2.75x EBITDA.
• Sensible use of proceeds. Management used the IPO mainly to repay debt rather than to chase more deals.

What could go wrong?

• Cash conversion. Adjusted EBITDA above 20% of revenue without matching free cash flow would push fair value toward the Bear. This is the main thesis breaker.
• Acquisition risk. Goodwill of $581.4 million and intangibles of $353.3 million are about 62% of assets. Acquired growth must earn more than its cost of capital.
• Balance sheet. Net debt of $418.7 million could rise again if a debt funded acquisition cycle resumes.
• Governance. A sponsor owning about 80% controls the vote, the company is a controlled company under NYSE rules, and the sponsor may sell shares over time.
• Government exposure. The filing notes routine government audits and investigations of contract costs and procurement. It says none is expected to be material, but defense budgets and program timing drive results.

Management execution

Management completed the IPO, repaid most of the debt, beat its own revenue plan in the second quarter and reaffirmed guidance. Against that, the adjusted EBITDA margin fell from 23.2% to 21.8% year over year during a period of rapid expansion, and the public record is too short for a normal three to five year review. The unresolved issue is the return on the acquisitions. Management credibility scores 12/20, good but unproven.

Stock Analyza scorecard

The valuation score is 47/100: discount to Base 16/40, protection against the Bear 10/20, agreement between methods 7/15, historical valuation 5/10 (neutral, no history), market implied expectations 7/10, data and model penalty 2/5. The price is below Base, but far above the buy price and close to the Bear.

Free cash flow per share growth cannot be measured with a few months of public history, so it is excluded and the remaining 10 points are rescaled to 12. The class holds either way, and a hard disqualifier for a Compounder applies anyway: growth that is mostly acquired without proven per share value creation.

Confidence score

What I would watch from here

The next review point is Q3 2026 results, expected in mid November 2026, and any change to guidance.

The three most important thesis breakers

1. Persistently poor conversion of adjusted EBITDA into free cash flow.
2. Acquisition returns below the cost of capital.
3. Renewed leverage or dilution without per share value creation.

Adversarial review

I recomputed every figure from the filings. The first draft's company inputs checked out: revenue, organic growth, adjusted EBITDA, guidance, backlog, cash, debt and share count all match the 10-Q and the earnings release. Several valuation steps did not hold up, and they were corrected.

The main changes: the primary value subtracted net debt projected for the end of 2027 while the market implied check used current net debt. A forward multiple applies to current net debt, and finance leases of $31.0 million belong in it. The secondary value applied a multiple to 2028 cash flow and compared it with a nearer dated value without discounting. The Bear and Bull values had no stated EBITDA; the Bull of $22.50 would have needed about $220 million of EBITDA at 19.5x, above the draft's own top case of $205 million, and the bottom row of its sensitivity table was $0.1 too high. Governance scored 5/5 despite a sponsor holding about 80% (now 2/5), economic return and cash flow quality were scored above what a return on capital of about 6% and negative free cash flow support, and a cyclical distortion flag had no cyclical driver behind it. The draft also had no peer table and no build of the 17x multiple, which I disclose rather than invent. The verdict is unchanged.

The strongest counter-argument is that the stock sits in a temporary post-IPO cash trough: with defense and space demand, $1.13 billion of backlog and margins above 20%, free cash flow could converge quickly toward EBITDA and the acquisitions could prove accretive. That is plausible and is the Bull case. It is not yet evidenced, because there is no normalized post-IPO free cash flow per share or acquisition return to point to. The opposite risk is that the shares are cheap for good reasons: the Bear sits only 13.9% below the price.

The Base ranges from $11.16 to $18.10, and the maximum buy price stays between $5.58 and $9.05, below the $12.03 price in every test. By the framework's default mapping an undervalued stock would be a buy, but the negative character change from an acquisition led expansion lowers the verdict one grade, and the price is far above any buy price. The publication gate status is PASS_WITH_WARNING.

Final verdict: hold at $12.03, watchlist for new money

Applied has real demand, a strong backlog and a repaired balance sheet, but the market has already marked down the stock by 40% from its IPO price, and the cash flow evidence is still missing. The price sits 19% below Base and near the Bear, and far above the margin of safety price.

Verdict: HOLD at $12.03, WATCHLIST for new money. Triangulated Base value $14.84, upside 23.3%, Confidence C (14/25). Required margin of safety 50%, maximum buy price $7.42.

For an existing holder, the demand and the deleveraging support holding. New money waits for $7.42 or below with the thesis intact, or for proof that EBITDA converts into free cash flow.

The main thesis breaker is adjusted EBITDA that fails to turn into durable free cash flow per share.

Sources

Primary sources include Applied's Form 10-Q for the quarter ended June 30, 2026, the Q2 2026 earnings release, the IPO prospectus and the Q2 2026 earnings call. The market price, trading range and revenue consensus come from StockAnalysis, which uses S&P Global data. The 2027 EBITDA and 2028 free cash flow figures are estimates from third party datasets, labeled as such.

The reference market price is $12.03, the September 30, 2026 regular session close. Balance sheet figures are as of June 30, 2026, shares as of August 5, 2026.